[Ip-health] PhRMA's reaction to Columbia's decision to cut prices

Baker, Brook b.baker at northeastern.edu
Wed Sep 14 11:08:41 PDT 2016

Not at all deterred by the critique in the UN Secretary-General's High Level Panel on Medicines final report about industry and government pressure on Columbia to threaten the issuance of a compulsory license, PhRMA today issued a verbal pout against Columbia lesser decision to require a price drop on Novartis's extortionately priced anti-cancer medicine, Gleevec:  http://phrma.org/press-release/phrma-response-to-colombias-decision-to-enforce-a-declaration-of-public-interest

Professor Brook K. Baker
Northeastern University School of Law
416 Huntington Ave.
Boston, MA 02115
(w) 617-373-3217
(c) 617-259-0760
(f) 617-373-5056
b.baker at neu.edu
Skype:  brook_baker

More information about the Ip-health mailing list